[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643939":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":41,"centralContacts":46,"locations":11,"responsibleParty":56,"collaborators":11,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":11,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":11,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":11,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":11},{"fullName":5,"class":6},"HK inno.N Corporation","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"IN-207907 120 mg","EXPERIMENTAL",null,[13],"Drug: IN-207907 120 mg",{"label":15,"type":10,"description":11,"interventionNames":16},"IN-207907 240 mg",[17],"Drug: IN-207907 240 mg",{"label":19,"type":10,"description":11,"interventionNames":20},"IN-207907 360 mg",[21],"Drug: IN-207907 360 mg",{"label":23,"type":24,"description":11,"interventionNames":25},"Placebo","PLACEBO_COMPARATOR",[26],"Drug: Placebo",[28,32,35,38],{"type":29,"name":9,"description":30,"armGroupLabels":31,"otherNames":11},"DRUG","IN-207907 120 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.",[9],{"type":29,"name":15,"description":33,"armGroupLabels":34,"otherNames":11},"IN-207907 240 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.",[15],{"type":29,"name":19,"description":36,"armGroupLabels":37,"otherNames":11},"IN-207907 360 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.",[19],{"type":29,"name":23,"description":39,"armGroupLabels":40,"otherNames":11},"Placebo will be administered by intravenous injection at 4-week intervals for a total of 3 doses.",[23],[42],{"name":43,"affiliation":44,"role":45},"Jae-Young Lim","Seoul National University Bundang Hospital","PRINCIPAL_INVESTIGATOR",[47,52],{"name":48,"role":49,"phone":50,"phoneExt":11,"email":51},"Yujin Choi","CONTACT","+82 31-5176-4668","yujin.choi@inno-n.com",{"name":53,"role":49,"phone":54,"phoneExt":11,"email":55},"Ahrong Kim","+82 31-5176-4666","ahrong.kim@inno-n.com",{"type":57,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100643939","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-in-207907-injection-in-elderly-patients-with-sarcopenia-100643939",false,"NCT07668180","A Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia","A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia","Inclusion Criteria:\n\n* Subjects aged ≥ 65 years (for female subjects, those who are medically unable to become pregnant)\n* Subjects diagnosed with sarcopenia in accordance with the Korean Working Group on Sarcopenia (KWGS) guidelines\n* Subjects with a body weight of ≥ 35 kg and a body mass index (BMI) of ≥ 15 kg\u002Fm² and \\\u003C 30 kg\u002Fm²\n* Subjects with a nutritional status screening score of ≥ 8 as assessed by the Mini Nutritional Assessment (MNA) questionnaire\n\nExclusion Criteria:\n\n* Subjects with a history of diseases or surgical procedures that may affect physical activity or function\n* Subjects with underlying muscle disorders, including myopathy or muscular atrophy\n* Subjects with neuromuscular or neurological disorders\n* Subjects with uncontrolled diabetes mellitus, severe renal impairment, uncontrolled thyroid disorders, vitamin D deficiency, severe hepatic impairment, severe cardiac disease, uncontrolled hypertension, respiratory disorders\n* Subjects with clinically significant findings on a 12-lead electrocardiogram (ECG)\n* Subjects who are positive for active hepatitis B, active hepatitis C, syphilis, or human immunodeficiency virus\n* Subjects with a history of malignancy within 5 years\n* Subjects who have received systemic immunosuppressants or immunostimulants\n* Subjects who have undergone treatment with plasmapheresis within 8 weeks\n* Subjects who have received treatment with medications prohibited in this clinical trial within 4 weeks\n* Subjects with hemoglobin levels \\\u003C 10 g\u002FdL\n* Subjects who have undergone surgery requiring general anesthesia within 4 weeks\n* Subjects who are unable to walk or are physically inactive\n* Subjects who are participating in or planning to participate in a separate high-intensity program for increasing muscle mass or strength during the clinical trial period\n* Subjects with severe psychiatric disorders such as major depression, schizophrenia, alcoholism, or drug dependence\n* Subjects with a score of \\\u003C 24 on the Korean version of the Mini Mental State Examination (MMSE-K)\n* Subjects with known allergies or hypersensitivity to the investigational product or its excipients","ALL","65 Years",{"count":68,"type":69},100,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","The goal of this clinical trial is to learn if intervention can treat sarcopenia in the elderly. Researchers will compare IN-207907 120 mg, 240 mg, 360 mg and placebo to see if SPPB score improves.",[75],"Sarcopenia in Elderly","NOT_YET_RECRUITING","2026-06-19",{"date":79,"type":80},"2026-06-25","ACTUAL",{"date":82,"type":69},"2026-09",{"date":84,"type":69},"2028-02",{"name":5,"class":6}]